First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

about

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q48921913

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@en

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@nl

type

Item

label

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@en

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@nl

prefLabel

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@en

First-line escalated BEACOPP d ...... refractory Hodgkin's lymphoma.

@nl

P1476

First-line escalated BEACOPP d ...... /refractory Hodgkin's lymphoma

@en

P2093

A Perrot

http://www.w3.org/2001/XMLSchema#string

A Stamatoullas-Bastard

http://www.w3.org/2001/XMLSchema#string

C Fermé

http://www.w3.org/2001/XMLSchema#string

C Fortpied

http://www.w3.org/2001/XMLSchema#string

C Herbaux

http://www.w3.org/2001/XMLSchema#string

D Ghez

http://www.w3.org/2001/XMLSchema#string

E Nicolas-Virelezier

http://www.w3.org/2001/XMLSchema#string

F L Bras

http://www.w3.org/2001/XMLSchema#string

H Khaled

http://www.w3.org/2001/XMLSchema#string

J-P Marolleau

http://www.w3.org/2001/XMLSchema#string

P2860

Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 t

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

P2888

bmt.2016.271

P304

310-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2016.271

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

René-Olivier Casasnovas

Nicolas Mounier

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27892946

http://www.w3.org/2001/XMLSchema#string